Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: BESIVANCE

« Back to Dashboard
Besivance is a drug marketed by Bausch And Lomb and is included in one NDA. It is available from two suppliers. There are seven patents protecting this drug.

This drug has sixty patent family members in nineteen countries.

The generic ingredient in BESIVANCE is besifloxacin hydrochloride. Two suppliers are listed for this compound. Additional details are available on the besifloxacin hydrochloride profile page.

Summary for Tradename: BESIVANCE

Patents:7
Applicants:1
NDAs:1
Suppliers: see list2

Pharmacology for Tradename: BESIVANCE

Ingredient-typeQuinolones
Drug ClassQuinolone Antimicrobial

Clinical Trials for: BESIVANCE

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYes8,604,020<disabled>Y<disabled>
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYes6,699,492<disabled>Y<disabled>
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYes8,415,342<disabled><disabled>
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYes5,447,926<disabled>YY<disabled>
Bausch And Lomb
BESIVANCE
besifloxacin hydrochloride
SUSPENSION/DROPS;OPHTHALMIC022308-001May 28, 2009RXYes8,481,526<disabled>Y<disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: BESIVANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications. They represent opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,732,415Topical treatment or prevention of ocular infections<disabled in preview>
7,056,893Topical treatment for prevention of ocular infections<disabled in preview>
5,385,900 Quinoline carboxylic acid derivatives<disabled in preview>
6,239,113 Topical treatment or prevention of ocular infections<disabled in preview>
6,569,443 Topical treatment or prevention of ocular infections<disabled in preview>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: BESIVANCE

Country Document Number Publication Date
World Intellectual Property Organization (WIPO)2010111116Sep 30, 2010
Japan2012521433Sep 13, 2012
Canada2368637Oct 05, 2000
Japan4994569Aug 08, 2012
Japan2010083901Apr 15, 2010
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc